Market News AIOpen the app

ImmunityBio, Inc. made the 2026 Deloitte Technology Fast 500 list for its big revenue growth in biotech.

MarketRead the original at prnewswire.com
Good for IBRX

ImmunityBio made Deloitte's 2026 list based on revenue growth from 2022 to 2025. This supports a favorable view of its business growth, though the source gives no growth rate.

IBRX · ImmunityBio, Inc.

AI read · Good for IBRX

The AI's read

This recognition reflects reported revenue growth over 3 years, giving evidence that ImmunityBio expanded its business. The source gives no growth rate or ranking, so it does not show how large or lasting that growth was.

Get alerts for IBRX

Follow ImmunityBio, Inc. (IBRX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for IBRX
Free on the App Store and Google Play, or on the web.